175 related articles for article (PubMed ID: 21370405)
1. RANKL expression is related to treatment outcome of patients with localized, high-grade osteosarcoma.
Lee JA; Jung JS; Kim DH; Lim JS; Kim MS; Kong CB; Song WS; Cho WH; Jeon DG; Lee SY; Koh JS
Pediatr Blood Cancer; 2011 May; 56(5):738-43. PubMed ID: 21370405
[TBL] [Abstract][Full Text] [Related]
2. Receptor activator of nuclear factor-kappaB ligand (RANKL) expression in hepatocellular carcinoma with bone metastasis.
Sasaki A; Ishikawa K; Haraguchi N; Inoue H; Ishio T; Shibata K; Ohta M; Kitano S; Mori M
Ann Surg Oncol; 2007 Mar; 14(3):1191-9. PubMed ID: 17195907
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of immunohistochemical expression of ezrin in non-metastatic high-grade osteosarcoma.
Ferrari S; Zanella L; Alberghini M; Palmerini E; Staals E; Bacchini P
Pediatr Blood Cancer; 2008 Apr; 50(4):752-6. PubMed ID: 17886294
[TBL] [Abstract][Full Text] [Related]
4. Expression of platelet-derived growth factor-AA is associated with tumor progression in osteosarcoma.
Sulzbacher I; Birner P; Trieb K; Träxler M; Lang S; Chott A
Mod Pathol; 2003 Jan; 16(1):66-71. PubMed ID: 12527715
[TBL] [Abstract][Full Text] [Related]
5. Primary osteogenic sarcoma with pulmonary metastasis: clinical results and prognostic factors in 91 patients.
Wu PK; Chen WM; Chen CF; Lee OK; Haung CK; Chen TH
Jpn J Clin Oncol; 2009 Aug; 39(8):514-22. PubMed ID: 19525290
[TBL] [Abstract][Full Text] [Related]
6. Osteosarcoma in the first decade of life.
Nagarajan R; Weigel BJ; Thompson RC; Perentesis JP
Med Pediatr Oncol; 2003 Nov; 41(5):480-3. PubMed ID: 14515397
[No Abstract] [Full Text] [Related]
7. Ephrin A4 expression in osteosarcoma, impact on prognosis, and patient outcome.
Abdou AG; Abd el-Wahed MM; Asaad NY; Samaka RM; Abdallaha R
Indian J Cancer; 2010; 47(1):46-52. PubMed ID: 20071790
[TBL] [Abstract][Full Text] [Related]
8. Prognostic relevance of increased angiogenesis in osteosarcoma.
Kreuter M; Bieker R; Bielack SS; Auras T; Buerger H; Gosheger G; Jurgens H; Berdel WE; Mesters RM
Clin Cancer Res; 2004 Dec; 10(24):8531-7. PubMed ID: 15623635
[TBL] [Abstract][Full Text] [Related]
9. Ezrin expression predicts survival in stage IIB osteosarcomas.
Kim MS; Song WS; Cho WH; Lee SY; Jeon DG
Clin Orthop Relat Res; 2007 Jun; 459():229-36. PubMed ID: 17353802
[TBL] [Abstract][Full Text] [Related]
10. "Osteosarcoma". A review of the management used and results in 28 patients.
Abdelnoor J; Kourani N; Semaan T
J Med Liban; 1992; 40(4):190-3. PubMed ID: 1339905
[TBL] [Abstract][Full Text] [Related]
11. P16 expression predicts necrotic response among patients with osteosarcoma receiving neoadjuvant chemotherapy.
Borys D; Canter RJ; Hoch B; Martinez SR; Tamurian RM; Murphy B; Bishop JW; Horvai A
Hum Pathol; 2012 Nov; 43(11):1948-54. PubMed ID: 22578565
[TBL] [Abstract][Full Text] [Related]
12. Increased RANKL expression is related to tumour migration and metastasis of renal cell carcinomas.
Mikami S; Katsube K; Oya M; Ishida M; Kosaka T; Mizuno R; Mochizuki S; Ikeda T; Mukai M; Okada Y
J Pathol; 2009 Aug; 218(4):530-9. PubMed ID: 19455604
[TBL] [Abstract][Full Text] [Related]
13. Impact of RANK signalling on survival and chemotherapy response in osteosarcoma.
Bago-Horvath Z; Schmid K; Rössler F; Nagy-Bojarszky K; Funovics P; Sulzbacher I
Pathology; 2014 Aug; 46(5):411-5. PubMed ID: 24842377
[TBL] [Abstract][Full Text] [Related]
14. Synchronous and metachronous skeletal osteosarcomas: the Norwegian Radium Hospital experience.
Brandal P; Bjerkehagen B; Bruland OS; Skjeldal S; Bogsrud TV; Hall KS
Acta Oncol; 2009; 48(8):1165-72. PubMed ID: 19863225
[TBL] [Abstract][Full Text] [Related]
15. KAI-1 expression in pediatric high-grade osteosarcoma.
Leavey PJ; Timmons C; Frawley W; Lombardi D; Ashfaq R
Pediatr Dev Pathol; 2006; 9(3):219-24. PubMed ID: 16944980
[TBL] [Abstract][Full Text] [Related]
16. Prostate-specific antigen modulates genes involved in bone remodeling and induces osteoblast differentiation of human osteosarcoma cell line SaOS-2.
Nadiminty N; Lou W; Lee SO; Mehraein-Ghomi F; Kirk JS; Conroy JM; Zhang H; Gao AC
Clin Cancer Res; 2006 Mar; 12(5):1420-30. PubMed ID: 16533764
[TBL] [Abstract][Full Text] [Related]
17. Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols.
Kager L; Zoubek A; Pötschger U; Kastner U; Flege S; Kempf-Bielack B; Branscheid D; Kotz R; Salzer-Kuntschik M; Winkelmann W; Jundt G; Kabisch H; Reichardt P; Jürgens H; Gadner H; Bielack SS;
J Clin Oncol; 2003 May; 21(10):2011-8. PubMed ID: 12743156
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of P-glycoprotein, HER-2/ErbB-2, p53, and Bcl-2 in primary tumor and metachronous lung metastases in patients with high-grade osteosarcoma.
Ferrari S; Bertoni F; Zanella L; Setola E; Bacchini P; Alberghini M; Versari M; Bacci G
Cancer; 2004 May; 100(9):1936-42. PubMed ID: 15112275
[TBL] [Abstract][Full Text] [Related]
19. Significant recent advances in the treatment of osteogenic sarcoma.
Cohen IJ
Isr J Med Sci; 1993 Nov; 29(11):748-53. PubMed ID: 8270413
[No Abstract] [Full Text] [Related]
20. Clinicopathologic analysis of HER-2/neu immunoexpression among various histologic subtypes and grades of osteosarcoma.
Kilpatrick SE; Geisinger KR; King TS; Sciarrotta J; Ward WG; Gold SH; Bos GD
Mod Pathol; 2001 Dec; 14(12):1277-83. PubMed ID: 11743051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
